We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Exc | EXC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.04 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.04 | 0.04 |
| Top Posts |
|---|
Posted at 04/11/2009 14:20 by knowing Come on EXC |
Posted at 01/10/2009 15:06 by topinfo PYC next EXCJust out Physiomics Trading Statement TIDMPYC RNS Number : 0816A Physiomics PLC 01 October 2009 ? Trading Update Physiomics plc ("Physiomics" or "the Company") Highlights: * Revenue for year ended 30 June 2009 is expected to exceed the forecast of GBP440k made in July 2008 * Good progress on Lilly collaboration, with license agreement signed in April 2009 * Achievement of second year milestone on Tempo project * Looking to leverage Physiomics' technology for non-pharmaceutical application Trading Update Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to update the market on its trading performance for the financial year ended 30 June 2009. Revenues for the year were stronger than anticipated in a previous trading statement issued on 28 July 2008 and we were able to build on the improvement set out in the Interim statement issued in February 2009. Conversion of debt into equity announced in August 2009 totalling GBP24k has also helped to reduce the deficit in equity shareholders' funds which stood at GBP102k at 31 December 2008. Since the publication of its interim results for the period ended 31 December 2008, Physiomics has made good progress with its collaboration with Eli Lilly and Company ("Lilly"), and in particular has announced on 2 April 2009 a license agreement with Lilly for a customised version of its "ModelPlayer(TM)" for in silico simulations of unspecified anticancer drugs. These are project specific licences. The Company is in discussion with a number of major players in the oncology sector and expects to be able to say more in the near future. Furthermore, Physiomics has announced on 23 June 2009 a successful evaluation, by the European Commission, of the results from the second year of the research program "TEMPO". This is the most important phase of the project and Physiomics' partners will start imminently to verify in an in vivo pre-clinical model the optimal chronotherapeutic schedules produced by Physiomics. When validated, this will served as a base for a further grant application, with the aim to test these chronotherapeutic schedules in a clinic setting. If the TEMPO approach is validated then it has both the potential to evaluate existing oncology compounds to see whether a more efficient dosing regimen is possible as well as helping formulate optimal study protocols for drugs used in combination therapy. This would provide data on the ideal dosing sequence, time interval between doses and amounts to be dosed. The biological models are supported by sophisticated simulation software environments developed by the team these include the Model Player(TM) and a version of the proprietary SystemCell technology running on the IBM "Blue C" super computer at the Institute of Life Sciences at Swansea University. We intend to leverage this technology platform for non-pharmaceutical application and we are looking at diversification in other areas and in particular Synthetic Biology. Commenting on the trading update, Physiomics' Chief Operating Officer, Dr Christophe Chassagnole, said: "We are really pleased to have exceeded our revenue forecast for the last year thanks to the good progress in our collaborations. Based on these achievements plus the recent technical development in the area of combination and scheduling and the potential to branch out into wholly new applications, we are confident that we can stimulate even greater interest in our technology." For further information: Physiomics plc Dr Christophe Chassagnole, COO +44 (0)1865 784980 WH Ireland Limited Katy Mitchell +44 (0) 161 832 2174 |
Posted at 01/10/2009 13:54 by knowing Thing is with EXC that the market has always kept a flat book on the stock. |
Posted at 01/10/2009 11:31 by 0verzeal Can EXC continue and be traded on Plus ?Thanks in anticipation. |
Posted at 27/8/2009 11:45 by wenlynn Stockport-based procurement services and equipment rental company EXC Plc (AIM: EXC) is giving "serious consideration" to delisting from the Alternative Investment Market, it said today (July 2009).EXC posted a loss of £1,097,000 (2007: £491,000 loss)for the year to December 2008, mostly due to the £518,000 cost of closing down Manchester-based leather jacket importer David Conrad (International) Ltd. Revenues from continuing operations were £1,468,000, generating a loss of £579,000. Chairman Michael Edelson said the company's sole trading business, Excalibur Ventures Ltd, generated lower levels of revenue than in prior years because customers were spending less due to the global economic slowdown. Excalibur's rental division, which hires out 28 pieces of heavy equipment to construction companies in the Middle East, managed to expand into a full scale operation during the year. It is less optimistic about its new specialised oil procurement services division, which has received no new orders. Losses are expected in the first half of 2009. Edelson said the board was looking at ways to cut group costs and was reviewing its listing in line with "many other AIM quoted companies". EXC Plc was incorporated in 2004 and listed on the AIM of the London Stock Exchange in July of the same year. Shares In Issue 353 Million John Michael Edelson - Chairman Simon Philip Larah - Chief Executive Elliot Richard Fidler - Finance Director Anthony Jack Leon - Non-Executive Director |
Posted at 02/4/2009 10:06 by haff1 ... SOME EXPLANATION FOR THIS MOVEMENT WOULDNT GO A MISS EXC?!!!!! |
Posted at 09/10/2008 07:56 by wenlynn "EXC plc posted a first-half pretax loss narrowed to 250,000 pounds from 664,000 pounds a year ago, based on revenue from continuing operations of 756,000 pounds. EXC -- which now only has one trading subsidiary, Excalibur Ventures -- said it expects to report a loss on continuing operations before tax for the full year but added the group is now well positioned to advance to its next level of development." |
Posted at 22/6/2008 20:36 by tornadodown Excalibur is a dynamic service related company, offering both procurement and specialized rental services. Excalibur's procurement services are based on extensive experience in the sourcing, procurement and supply of a wide range of equipment on a global scale. We offer a bespoke rental solution for our customer's specific needs. Excalibur identifies its customers' needs quickly and efficiently resulting in the timely delivery of materials. Excalibur's customers are primarily large multinational companies and government operations involved in infrastructure and support projects. Excalibur is a UK private limited company and a subsidiary of a UK listed company. Its head office is in the UK with operations in Europe, the Middle East and the USA. |
Posted at 01/5/2008 21:40 by topvest Yes, that was my thinking. I think the original plan was Excalibur, hence the name EXC, but at some stage they acquired the dodgy leather dealer at initial float. Leather is a dying trade imho, but Excalibur lookss very interesting under the young and entrepeneurial leadership if the MD. |
Posted at 12/4/2008 09:07 by topvest I think that is from a while back, but Excalibur has a young dynamic MD and has good prospects. Never quite sure why they pushed the leather business into EXC in the first place as it didn't fit with Excalibur. We are now back to where this all started off and Excalibur should have good prospects, particularly at a £0.5m market cap. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
